🚨 Eli Lilly just dropped Phase 3 data on retatrutide: 20.8% average weight loss over 80 weeks
BLA filing planned for Q1 2027. This is the obesity drug race heating up—$LLY positioning for next-gen GLP-1 dominance.
Watch how this moves pharma narratives and potentially crypto health/longevity plays if tokenized health data or DeSci protocols catch the wave.
Not financial advice but obesity pharma = multi-hundred billion TAM. Eyes on $LLY and any Web3 intersections.
BLA filing planned for Q1 2027. This is the obesity drug race heating up—$LLY positioning for next-gen GLP-1 dominance.
Watch how this moves pharma narratives and potentially crypto health/longevity plays if tokenized health data or DeSci protocols catch the wave.
Not financial advice but obesity pharma = multi-hundred billion TAM. Eyes on $LLY and any Web3 intersections.
